USA approves emergency use of Regeneron's antibody cocktail for Covid-19 therapy

Modesto Morganelli
Novembre 22, 2020

In October, Trump credited his recovery to antibody treatments from Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals Inc.'s antibody cocktail received an emergency use authorization from USA drug regulators for treatment of early COVID-19 symptoms, adding to the expanding arsenal of therapies available to physicians.

Regeneron's chief executive officer, Dr. Leonard S. Schleifer, said in a statement that demand may initially exceed supply, "making it even more critical that federal and state governments ensure REGEN-COV2 is distributed fairly and equitably to the patients most in need".

There's no way to know whether the Regeneron drug helped Trump recover; he received a host of treatments and most COVID-19 patients recover on their own.

Regeneron said it will have enough of the drug to treat 80,000 patients by the end of this month, and 300,000 patients by the end of January.

Unlike some other drugs used for Covid-19, the antibody cocktail is meant to be given early in infection, before patients are hospitalized or require oxygen therapy.

The drug company, which started clinical trials on June 11, said that preliminary results from a trial reveal that its antibody treatment could reduce the severity of the virus in non-hospitalised patients with Covid-19.

"The safety and effectiveness of this investigational therapy for use in the treatment of COVID-19 continues to be evaluated".

The FDA's authorization is limited to high-risk patients, like those who are older than 65 years of age or have a BMI greater than or equal to 35.

Initial supplies will likely be vastly outstripped by demand as the USA has surged past 10 million reported cases, with the country facing what health experts say will be a dark winter due uncontrolled spread of the virus. Antibodies are proteins that the body produces to fight off infection and diseases. "Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our healthcare system".

As TheBlaze reported, Carson contracted COVID-19 about two weeks ago.

FDA regulators authorized the Regeneron drug using their emergency powers to quickly speed the availability of experimental drugs and other medical products during public health crises.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE